Whole bladder photodynamic therapy with 5-aminolevulinic acid using a white light source

Urology

Volumn 61, Issue 2, 2003, Pages 332-337

  Waidelich, R ^a   Beyer, W ^b   Knuchel R ^b   Stepp, H ^b   Baumgartner, R ^b   Schroder J ^b   Hofstetter, A ^b   Kriegmair, M ^b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMINOLEVULINIC ACID;

ARTICLE; BLADDER BIOPSY; BLADDER CAPACITY; CANCER CELL; CANCER CELL DESTRUCTION; CANCER RECURRENCE; CARCINOMA IN SITU; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FOLLOW UP; HISTOLOGY; HUMAN; INFORMED CONSENT; MULTIPLE CANCER; PAPILLOMA; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RADIATION DOSE; URINARY FREQUENCY; URINARY URGENCY; UROGENITAL TRACT CANCER; UROGENITAL TRACT TUMOR; WHITE LIGHT;

EID: 0037322545     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(02)02164-7     Document Type: Article

References (28)

1. Nseyo U.O., Shumaker B., Klein E.A., et al. Photodynamic therapy using porfimer sodium as an alternative to cystectomy in patients with refractory transitional cell carcinoma in situ of the bladder. J Urol. 160:1998;39-44.
2. Kriegmair M., Waidelich R., Lumper W., et al. Integral photodynamic treatment of refractory superficial bladder cancer. J Urol. 154:1995;1339-1341.
3. Waidelich R., Stepp H., Baumgartner R., et al. Clinical experience with 5-aminolevulinic acid and photodynamic therapy for refractory superficial bladder cancer. J Urol. 165:2001;1904-1907.
4. Benson R.C., Kinsey J.H., Cortese D.A., et al. Treatment of transitional cell carcinoma of the bladder with hematoporphyrin derivative phototherapy. J Urol. 130:1983;1090-1095.
5. Jocham D., Baumgartner R., Stepp H., et al. Clinical experience with the integral photodynamic therapy of bladder carcinoma. J Photochem Photobiol B. 6:1990;183-187.
6. D'Hallewin M.-A., Baert L. Long-term results of whole bladder wall photodynamic therapy for carcinoma in situ of the bladder. Urology. 45:1995;763-767.
7. Walther M.C.C., Delaney T.F., Smith P.D., et al. Phase I trial of photodynamic therapy in the treatment of recurrent superficial transitional cell carcinoma of the bladder. Urology. 50:1997;199-206.
8. Kriegmair M., Baumgartner R., Lumper W., et al. Early clinical experience with 5-aminolevulinic acid for the photodynamic therapy of superficial bladder cancer. Br J Urol. 77:1996;667-671.
9. Kelly J.F., Snell M.E. Hematoporphyrin derivative a possible aid in the diagnosis and therapy of carcinoma of the bladder . J Urol. 115:1976;150-151.
10. Kriegmair M., Baumgartner R., Knchel R., et al. Detection of early bladder cancer by 5-aminolevulinic acid induced porphyrin fluorescence. J Urol. 155:1996;105-110.
11. Zaak D., Kriegmair M., Stepp H., et al. Endoscopic detection of transitional cell carcinoma with 5-aminolevulinic acid results of 1012 fluorescence endoscopies . Urology. 57:2001;690-694.
12. Harty J.I., Amin M., Wieman T.J., et al. Complications of whole bladder dihematoporphyrin ether photodynamic therapy. J Urol. 141:1989;1341-1346.
13. Nseyo U.O., Lundahl S.L., Merrill D.C. Whole bladder photodynamic therapy critical review of present-day technology and rationale for development of intravesical laser catheter and monitoring system . Urology. 36:1990;398-402.
14. Steinbach P., Kriegmair M., Baumgartner R., et al. Intravesical instillation of 5-aminolevulinic acid the fluorescent metabolite is limited to urothelial cells . Urology. 44:1994;676-681.
15. Chang S.-C., MacRobert A.J., Bown S.G. Photodynamic therapy on rat urinary bladder with intravesical instillation of 5-aminolevulinic acid light diffusion and histological changes . J Urol. 155:1996;1749-1753.
16. Ghadially FN: Mitochondria, in Ghadially FN (Ed): Ultrastructural Pathology of the Cell and Matrix, 4th ed. Boston, Butterworth-Heinemann, 1997, vol 1, pp 195-327.
17. Seidl J., Rauch J., Krieg R.C., et al. Optimization of differential photodynamic effectiveness between normal and tumor urothelial cells using 5-aminolevulinic acid induced protoporphyrin IX as sensitizer. Int J Cancer. 92:2001;671-677.
18. Grönlund-Pakkanen S., Pakkanen T.M., Talja M., et al. The morphological changes in rat bladder after photodynamic therapy with 5-aminolevulinic acid-induced protoporphyrin IX. Br J Urol. 86:2000;126-132.
19. Henderson B.W., Vaughan L., Bellnier D.A., et al. Photosensitization of murine tumor, vasculature and skin by 5-aminolevulinic acid-induced porphyrin. Photochem Photobiol. 62:1995;780-789.
20. Peng Q., Berg K., Moan J., et al. 5-aminolevulinic acid-based photodynamic therapy principles and experimental research . Photochem Photobiol. 65:1997;235-251.
21. Manyak M.J. Photodynamic therapy principles and urologic applications . Semin Urol. 9:1991;192-202.
22. Walther M.C.C.M. The role of photodynamic therapy in the treatment of recurrent superficial bladder cancer. Urol Clin North Am. 27:2000;163-170.
23. Herman M.A., Webber J., Fromm D., et al. Hemodynamic effects of 5-aminolevulinic acid in humans. J Photochem Photobiol B Biol. 43:1998;61-65.
24. Waidelich R., Stepp H., Baumgartner R., et al. Clinical experience with 5-aminolevulinic acid and photodynamic therapy for refractory superficial bladder cancer. J Urol. 165:2001;1904-1907.
25. Waidelich R., Hofstetter A., Stepp H., et al. Early clinical experience with 5-aminolevulinic acid for the photodynamic therapy of upper tract urothelial tumors. J Urol. 159:1998;401-404.
26. 15N. Biochem J. 64:1956;80-89.
27. Dalton J.T., Yates C.R., Yin D., et al. Clinical pharmacokinetics of 5-aminolevulinic acid in healthy volunteers and patients at high risk for recurrent bladder cancer. J Pharmacol Exp Ther. 301:2002;507-512.
28. Mostofi F.K., Sorbin L.H., Torloni H., et al. Histological typing of urinary bladder tumors, in International Classification of Tumors No. 19. 1973;World Health Organization, Geneva.